Abstract:Introduction: Allergic reactions are mediated by human IgE antibodies that bind to and cross-link allergen molecules. The sites on allergens that are recognized by IgE antibodies have been difficult to investigate because of the paucity of IgE antibodies in a human serum. Here, we report the production of unique human IgE monoclonal antibodies to major inhaled allergens and food allergens that can be produced at scale in perpetuity. Materials and methods: The IgE antibodies were derived from peripheral blood mononuclear cells of symptomatic allergic patients, mostly children aged 3-18 years, using hybridoma fusion technology. Total IgE and allergen-specific IgE was measured by ImmunoCAP. Their specificity was confirmed through ELISA and immunoblotting. Allergenic potency measurements were determined by ImmunoCAP inhibition. Biological activity was determined in vitro by comparing β-hexosaminidase release from a humanized rat basophilic cell line. Results: Human IgE monoclonal antibodies (n = 33) were derived from 17 allergic patients with symptoms of allergic rhinitis, asthma, atopic dermatitis, food allergy, eosinophilic esophagitis, or red meat allergy. The antibodies were specific for five inhaled allergens, nine food allergens, and alpha-gal and had high levels of IgE (53,450-1,702,500 kU/L) with ratios of specific IgE to total IgE ranging from <0.01 to 1.39. Sigmoidal allergen binding curves were obtained through ELISA, with low limits of detection (<1 kU/L). Allergen specificity was confirmed through immunoblotting. Pairs of IgE monoclonal antibodies to Ara h 6 were identified that cross-linked after allergen stimulation and induced release of significant levels of β-hexosaminidase (35%-80%) from a humanized rat basophilic cell line. Conclusions: Human IgE monoclonal antibodies are unique antibody molecules with potential applications in allergy diagnosis, allergen standardization, and identification of allergenic epitopes for the development of allergy therapeutics. The IgE antibody probes will enable the unequivocal localization and validation of allergenic epitopes.

Determination of IgE functional epitope and molecular design of IgE antagonist:research advance

Generation of IgE-specific Cytotoxic T Lymphocytes As a Novel Immunotherapeutic Approach for the Treatment of Allergic Asthma.

Reduction of Serum IgE by Depletion of the IgE B Cell Lineage - a Novel Approach for the Treatment of Allergic Diseases (140.7)

Antibodies Specific for a Segment of Human Membrane IgE Deplete IgE-producing B Cells in Humanized Mice.

Effect of antigen binding affinity and effector function on the pharmacokinetics and pharmacodynamics of anti-IgE monoclonal antibodies

Aiming to IgE: Drug development in allergic diseases

A Comparison of Natural and Therapeutic Anti-IgE Antibodies

Precision engineering for localization, validation and modification of allergenic epitopes

Advances in targeted drugs for allergic diseases

Research progress of anti-IgE monoclonal antibody omalizumab in the treatment of asthma

Reduction of Circulating IgE and Allergens by a Ph-Sensitive Antibody with Enhanced FcγRIIb Binding

A therapeutic strategy to target distinct sources of IgE and durably reverse allergy

Design of an Ara h 2 hypoallergen from conformational epitopes

The Application of Anti-Ige Antibody in the Treatment of Bronchial Asthma

Enzymatic Hydrolysis-Assisted Magnetic Beads Adsorption for Precise Localization of IgE-linear Epitopes in Ovalbumin and the Mechanism of Reduced Allergenicity after Enzymatic Hydrolysis

Unique allergen-specific human IgE monoclonal antibodies derived from patients with allergic disease

IgE binding epitope mapping with TL1A tagged peptides

Fine epitope mapping of humanized anti-IgE monoclonal antibody omalizumab.

Structure-guided Engineering of Aptamers to Enhanced Structural Stability and Application Performance in Alleviating Β-Lactoglobulin Allergenicity

Discovery of Potent Antiallergic Agents Based on an O-Aminopyridinyl Alkynyl Scaffold

“Relative Symmetry with Electronegativity of Different Key-Groups” Strategy for MRGPRX2 Antagonist Design and Its Effect on Antigen-Induced Pulmonary Inflammation